Philippe M. R. Guinot
Director/Board Member at BioVex, Inc.
Philippe M. R. Guinot active positions
| Companies | Position | Start | End |
|---|---|---|---|
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Director/Board Member | 14/05/2009 | - |
Career history of Philippe M. R. Guinot
Former positions of Philippe M. R. Guinot
| Companies | Position | Start | End |
|---|---|---|---|
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Chairman | - | 26/06/2018 |
Omnes Capital SAS /Venture/
 Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Private Equity Investor | 30/06/2001 | 31/03/2011 |
BioVex Ltd.
 BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | 31/12/2002 | 03/03/2011 |
Diatos SA
 Diatos SA Pharmaceuticals: MajorHealth Technology Diatos SA develops innovative therapies for the treatment of cancer. The firm leverages its peptide-based, intracellular drug delivery & tumor targeting technologies to improve the properties of existing therapeutics. Its products include DaunoXome, DTS-301 and DTS-108. The company was founded in 1999 and headquartered in Paris, France. | Director/Board Member | - | 14/09/2009 |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Director/Board Member | 31/12/2005 | 31/12/2006 |
Beaufour Ipsen Pharma SAS
 Beaufour Ipsen Pharma SAS Pharmaceuticals: OtherHealth Technology Beaufour Ipsen Pharma SAS develops and manufactures pharmaceutical products. The company specializes in the development and production of controlled release formulation for therapeutic peptides used in the treatment of hormone responsive illnesses. The firm was founded in 1929 by Henri Beaufour and is headquartered in Paris, France. | Corporate Officer/Principal | - | - |
Era Biotech SA
 Era Biotech SA Miscellaneous Commercial ServicesCommercial Services Era Biotech SA is a biotechnology company that specializes in enzymes and recombinant vaccines. It develops and produces vaccines for human and animal health, therapeutic peptides, and industrial enzymes. The company was founded in August 2002 and is headquartered in Barcelona, Spain. | Director/Board Member | 20/07/2010 | - |
| METABOLIC EXPLORER | Director/Board Member | 20/07/2010 | - |
| Independent Dir/Board Member | 31/12/2001 | - | |
| ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░ ░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Statistics
International
| France | 6 |
| United States | 3 |
| United Kingdom | 3 |
Operational
| Director/Board Member | 10 |
| Private Equity Investor | 1 |
| Independent Dir/Board Member | 1 |
Sectoral
| Health Technology | 8 |
| Commercial Services | 5 |
| Process Industries | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| METABOLIC EXPLORER | Process Industries |
| Private companies | 12 |
|---|---|
Diatos SA
Diatos SA Pharmaceuticals: MajorHealth Technology Diatos SA develops innovative therapies for the treatment of cancer. The firm leverages its peptide-based, intracellular drug delivery & tumor targeting technologies to improve the properties of existing therapeutics. Its products include DaunoXome, DTS-301 and DTS-108. The company was founded in 1999 and headquartered in Paris, France. | Health Technology |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Health Technology |
PanGenetics BV
 PanGenetics BV Miscellaneous Commercial ServicesCommercial Services PanGenetics BV researches and develops antibody-based therapeutic products. It specializes in taking antibodies at the late research stage through to clinical proof of concept. The firm’s advanced programs are PG102, a CD40 antagonist, and PG110, an anti-Nerve Growth Factor antibody for use in chronic pain. The company was founded by Mark de Boer and James W. Larrick in 1995 and is headquartered in Utrecht, the Netherlands. | Commercial Services |
Beaufour Ipsen Pharma SAS
Beaufour Ipsen Pharma SAS Pharmaceuticals: OtherHealth Technology Beaufour Ipsen Pharma SAS develops and manufactures pharmaceutical products. The company specializes in the development and production of controlled release formulation for therapeutic peptides used in the treatment of hormone responsive illnesses. The firm was founded in 1929 by Henri Beaufour and is headquartered in Paris, France. | Health Technology |
BioVex Ltd.
BioVex Ltd. Miscellaneous Commercial ServicesCommercial Services BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Cytheris SA
 Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Health Technology |
Omnes Capital SAS /Venture/
Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Finance |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Era Biotech SA
Era Biotech SA Miscellaneous Commercial ServicesCommercial Services Era Biotech SA is a biotechnology company that specializes in enzymes and recombinant vaccines. It develops and produces vaccines for human and animal health, therapeutic peptides, and industrial enzymes. The company was founded in August 2002 and is headquartered in Barcelona, Spain. | Commercial Services |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |